Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC
Not Applicable
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000035853
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing particular
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival (PFS) Overall survival (OS) One-year overall survival Two-year overall survival Presence or absence of progression Pattern of progression (Presence or absence of progression of brain metastasis) Post-treatment: 2nd treatment after the failure of alectinib treatment
- Secondary Outcome Measures
Name Time Method